Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 6/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.59 |
| ▸ | DRD2 | P14416 | 7/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 7/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.48 |
| ▸ | HTR1A | P08908 | 3/20 | 0.46 |
| ▸ | HTR1D | P28221 | 3/20 | 0.46 |
| ▸ | HTR1B | P28222 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | HTR2B | P41595 | 3/20 | 0.46 |
| ▸ | HTR6 | P50406 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR1E | P28566 | 2/20 | 0.46 |
| ▸ | HTR1F | P30939 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.46 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3619175 | 0.85 | KEAP1 (0.54) | KEAP1NFE2L2HTR6SMN1; SMN2GAA | |
| SCHEMBL1377296 | 0.82 | HTR6 (0.54) | KEAP1DRD2ADRA1BHTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL6047109 | 0.81 | HTR6 (0.53) | KEAP1DRD2ADRA1BHTR1AHTR1D | |
| SCHEMBL3622984 | 0.81 | GAA (0.50) | DRD2ADRA1BHTR1AHTR1DHTR1B | |
| SCHEMBL3623978 | 0.81 | KEAP1 (0.62) | KEAP1NFE2L2HTR6BRPF1 | |
| SCHEMBL3619654 | 0.81 | ALDH1A1 (0.57) | SMN1; SMN2GAATDP1 | |
| Hydrochloric Acid SCHEMBL6047567 | 0.80 | GAA (0.49) | GAACACNA1H | |
| SCHEMBL3626316 | 0.79 | KEAP1 (0.69) | KEAP1NFE2L2HTR1AHTR2BHTR6 | |
| SCHEMBL4310249 | 0.71 | KMT2A (0.50) | DRD2ADRA1BHTR1AHTR1DHTR1B | |
| SCHEMBL3620352 | 0.71 | MAPT (0.66) | DRD2ADRA1BHTR1AHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | disclosed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-7144883-B2 | Bicyclic sulfonamide compounds | BIOVITRUM AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | disclosed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | KEAP1 1645/4885NFE2L2 597/4885DRD2 2808/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | KEAP1 1144/4885NFE2L2 406/4885DRD2 2846/4885 |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | SULT2A1, SULT1A1, SULT1E1 | KEAP1 309/4885NFE2L2 24/4885DRD2 2155/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | KEAP1 1144/4885NFE2L2 406/4885DRD2 2846/4885 |
| US-20100222330-A1 | New Compounds | SULT2A1, GPR119, STS | KEAP1 1645/4885NFE2L2 597/4885DRD2 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.